Search filters
Filters
Clear All

Phase

  • 2
  • 1
  • 30
  • 33
  • 25
  • 33

Found 33 dm-gastroenterology trials

A listing of dm-gastroenterology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

ATLAS-UC

99 or below
All genders
To evaluate the efficacy, safety, and tolerability of multiple does strengths of MK-7240 IV infusion and subcutaneous injection compared to Placebo as assessed by the proportion of participants achieving clinical remission per Modified Mayo Score, endoscopic improvements, at designated time points. Participants aged 16 to 75 years (inclusive) with moderately …
Learn More

PHIN-001

99 or below
All genders
Please see section 2 of the protocol, under "Introduction" for a list of study objectives. Please see section 2 of the protocol, under "Objectives" for a list of primary outcome variables. Please see section 2 of the protocol, under "Objectives" for a list of secondary outcome variables.
Learn More

AK-US-001-0105

99 or below
All genders
The primary objective of this study is to evaluate the effect of EFX compared to placebo on achieving NASH resolution AND fibrosis regression in subjects with fibrosis stage 2 or 3 at Week 52. Subjects meeting the study's eligibility criteria will randomly assigned in a 1:1:1 ratio to 1 of …
Learn More

AK-US-001-0107

99 or below
All genders
This is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of EFX in subjects with noninvasively diagnosed NASH/NAFLD. Subjects will be dosed QW with EFX 50 mg or placebo for up to 52 weeks. The safety and tolerability of EFX will be assessed during the study …
Learn More

CVC-HCC

99 or below
All genders
The overarching goal of our Clinical Validation Center for Hepatocellular Carcinoma (CVC-HCC) is to develop a robust infrastructure that will support efficient validation of emerging HCC biomarkers. Our CVC-HCC will also conduct studies to validate novel blood and imaging biomarkers to improve risk stratification and early detection in patients with …
Learn More

A Study to Investigate the Efficacy and Safety of Solrikitug in Adults with Eosinophilic Esophagitis

99 or below
All genders
Solrikitug is a humanized immunoglobulin (Ig) G1 monoclonal antibody that binds to human thymic stromal lymphopoietin TSLP is an up-stream regulator of the T-helper 2 immune response and has been shown to drive the Th2 inflammatory responses that are involved in allergic inflammatory disorders, including eosinophilic esophagitis (EoE). This is …
Learn More

TRACER

99 or below
All genders
There is evidence that GALAD, a score that incorporates 3 blood based biomarkers and patient age and sex may be more effective than standard of care screening at detecting HCC early in patients with liver cirrhosis or chronic hepatitis B. Patients undergoing liver cancer screening will be enrolled, then randomized …
Learn More

IDEAL

99 or below
All genders
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 study Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Learn More

BHB-FAP

99 or below
All genders
Determine whether oral BHB supplementation is safe and tolerable in FAP. Determine whether oral BHB supplementations increases serum BHB levels in FAP. Investigate whether oral BHB supplementation leads to transcription and protein expression changes in the intestinal mucosa and polyps in FAP. Elucidate whether oral BHB supplementation in FAP reduces …
Learn More

GSK B-United

99 or below
All genders
To evaluate the efficacy and safety of 2 different doses of daplusiran/tomligisiran (50 mg every 4 weeks and 200 mg every 4 weeks for a total of 6 doses) followed by bepirovirsen 300 mg weekly for 24 weeks (with loading doses) in people living with chronic HBV on nucleos(t)ide analogue …
Learn More
21 - 30 of 33